• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Otonomy Inc.

    4/22/22 4:01:54 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OTIC alert in real time by email
    SC 13G 1 d710404dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    Otonomy, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    68906L105

    (CUSIP Number)

    April 16, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 68906L105

     

      1.    

      Names of Reporting Persons.

     

      David Allen Weber

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      3,006,871 (See Item 4(a) below)

       6.  

      Shared Voting Power

     

      -0-

       7.  

      Sole Dispositive Power

     

      3,006,871 (See Item 4(a) below)

       8.  

      Shared Dispositive Power

     

      -0-

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      3,006,871 (See Item 4(a) below)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.0% (See Item 4(b) below)

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     


    Item 1(a) Name of Issuer:

    Otonomy, Inc.

    Item 1(b) Address of Issuer’s Principal Executive Offices:

    4796 Executive Drive

    San Diego, CA 92121

    Item 2 (a) Name of Person Filing:

    David Allen Weber

    Item 2 (b) Address of Principal Business Office or, if none, Residence:

    c/o Otonomy, Inc.

    4796 Executive Drive

    San Diego, CA 92121

    Item 2 (c) Citizenship:

    David Allen Weber is a United States citizen.

    Item 2 (d) Title of Class of Securities:

    Common Stock, par value $0.001 per share

    Item 2 (e) CUSIP Number:

    68906L105

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or 240.13d-2(c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership

     

      (a)

    Amount beneficially owned:

    As of April 16, 2022, David Allen Weber had sole voting and dispositive power over the following shares: (i) 45,435 shares of Common Stock held by David Allen Weber, (ii) 21,876 shares of Common Stock held by The Weber Trust Dated March 9, 2005 for which Dr. Weber serves as trustee, and (iii) 2,939,560 shares of Common Stock subject to stock options exercisable within 60 days of April 16, 2022.

     

      (b)

    Percent of class:

    5.0%

    The ownership percentage above is calculated based on (i) 56,732,474 shares of Common Stock outstanding as of February 22, 2022 as reported in the Company’s Annual Report on Form 10-K, and (ii) 2,939,560 shares of Common Stock subject to stock options exercisable within 60 days of April 16, 2022.


      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or direct the vote: 3,006,871 shares

     

      (ii)

    Shared power to vote or direct the vote:-0-

     

      (iii)

    Sole power to dispose or to direct the disposition of: 3,006,871 shares

     

      (iv)

    Shared power to dispose or to direct the disposition of: -0- shares

     

    Item 5.

    Ownership of 5 Percent or Less of a Class

    Not applicable.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certifications

    Not applicable.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: April 21, 2022

     

    /s/ David Allen Weber

    David Allen Weber, Ph.D.

    Get the next $OTIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OTIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTIC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Otonomy Inc.

      15-12G - OTONOMY, INC. (0001493566) (Filer)

      4/4/23 3:40:49 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Otonomy Inc.

      EFFECT - OTONOMY, INC. (0001493566) (Filer)

      4/3/23 12:15:10 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Otonomy Inc.

      EFFECT - OTONOMY, INC. (0001493566) (Filer)

      4/3/23 12:15:09 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Otonomy Announces Change in Stock Exchange Listing

      SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company's shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company's shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications Staff (the Staff) had determined to delist the company's securities unless the company timely requested a hearing before the Nasdaq Hearings Panel (the Pan

      12/22/22 7:53:14 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Provides Corporate Update

      SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of Strategic Options As previously reported, Otonomy initiated an evaluation of strategic options to realize value from its pipeline. The

      12/19/22 4:53:38 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints in a Phase 2 clinical trial in tinnitus patients. Based on these results, Otonomy discontinued development of OTO-313 and implemented other measures to extend its cash runway. Th

      11/10/22 4:05:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Financials

    Live finance-specific insights

    See more
    • Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment completed for higher dose evaluation with top-line results expected in fourth quarter of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop

      7/25/22 4:05:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

      SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.  A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minu

      7/18/22 7:30:00 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoingOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) --  Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today repor

      5/9/22 4:04:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/14/23 4:06:58 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/13/23 8:49:22 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/10/23 4:29:37 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Otonomy Appoints Jill Broadfoot to Board of Directors

      SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors. "Jill is an excellent addition to the board with strong strategic, operational and financial expertise within the biopharmaceutical sector," said David A. Weber, Ph.D., president and CEO of Otonomy. "We are excited to welcome her as we continue our growth trajectory and make progress to achieving our clinical milestones." Since 2018, Ms. Broadfoot has served as chief financial officer (CFO) of aTyr Pharma, Inc., a biotherapeutics company. P

      8/19/21 7:30:00 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Hogan H Michael Iii

      3 - OTONOMY, INC. (0001493566) (Issuer)

      2/24/23 4:53:45 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Weber David Allen covered exercise/tax liability with 91,636 shares, decreasing direct ownership by 24% to 285,863 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:31:39 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cayer Paul E covered exercise/tax liability with 40,054 shares, decreasing direct ownership by 18% to 183,733 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:30:19 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright reiterated coverage on Otonomy with a new price target

      HC Wainwright reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

      3/1/21 8:38:28 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Otonomy with a new price target

      HC Wainwright & Co. reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

      2/23/21 6:53:19 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler reiterated coverage on Otonomy with a new price target

      Piper Sandler reiterated coverage of Otonomy with a rating of and set a new price target of $5.00 from $10.00 previously

      2/22/21 3:01:01 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care